No guidelines matched your search.
Try a shorter keyword like "MASLD", "fibrosis", or "Baveno".
MASLD / MASH β Assessment & Nomenclature
Guidelines covering the diagnosis, screening, and classification of metabolic dysfunctionβassociated steatotic liver disease (formerly NAFLD/NASH).
Why NAFLD was renamed to MASLD and NASH to MASH, how MASLD is defined using cardiometabolic risk criteria, the five-category SLD classification, and what changed (and didn't) for your diagnosis.
Who should be screened for fatty liver fibrosis, the FIB-4 β FibroScan/ELF two-step algorithm, what lifestyle changes help, and which medications may benefit patients β the AASLD's comprehensive practice guidance.
Portal Hypertension & Varices
Guidelines on diagnosing clinically significant portal hypertension, managing varices, and preventing variceal bleeding in patients with cirrhosis.
FibroScan thresholds for ruling in/out portal hypertension, the Rule of 5, when you can skip endoscopy, how beta-blockers help, variceal bleeding management, and the concept of recompensation.
Non-invasive CSPH diagnosis, who should receive beta-blockers or band ligation, how acute variceal bleeding is managed with endoscopy and TIPS, and preventing rebleeding β the AASLD's updated practice guidance.
Treatment β MASH Pharmacotherapy
Drug-specific guidance for FDA-approved (accelerated) therapies targeting MASH with fibrosis β who qualifies, monitoring protocols, and trial results.
Who qualifies for resmetirom, what non-invasive tests you need, how doctors monitor treatment response, drug interactions to watch for, and side effects β based on the MAESTRO-NASH trial results.
Who qualifies for semaglutide, the non-invasive testing pathway, how doctors monitor your response, and what side effects to expect β based on the ESSENCE trial and the AASLD's latest practice guidance.
More Guidelines Coming Soon
We're expanding this library with additional society guidelines and consensus statements. Future additions will include: